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Diet composition may affect the onset and progression of chronic degenerative 
diseases, including cancer, whose pathogenesis relies on inflammatory processes. 
Growing evidence indicates that diet and its components critically contribute to human 
health, affecting the immune system, secretion of adipokines, and metabolic pathways. 
Colorectal cancer (CRC) is one of the leading causes of death worldwide. Antineoplastic 
drugs are widely used for CRC treatment, but drug resistance and/or off-target toxicity 
limit their efficacy. Dietary ω3 polyunsaturated fatty acids (PUFA) have been gaining great 
interest in recent years as possible anti-inflammatory and anticancer agents, especially 
in areas such as the large bowel, where the pro-inflammatory context promotes virtually 
all steps of colon carcinogenesis. Growing epidemiological, experimental, and clinical 
evidence suggests that ω3 PUFA may play a role in several stages of CRC management 
exhibiting antineoplastic activity against human CRC cells, improving the efficacy of radi-
ation and chemotherapy, ameliorating cancer-associated secondary complications, and 
preventing CRC recurrence. These effects are most likely related to the immunomodula-
tory activities of ω3 PUFA that are able to influence several aspects of the inflammatory 
process ranging from inflammasome activation, leukocyte recruitment, production of 
immune mediators to differentiation, and activation of immune cells. In this review, we 
will focus on the potential use of ω3 PUFA as adjuvant agents together with chemo/
radiotherapy, highlighting the immunomodulatory effects most likely responsible for their 
beneficial effects in different stages of CRC management.
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inTRODUCTiOn
It has become increasingly clear that dietary habits may affect the risk/progression of chronic dis-
eases with a pathogenic inflammatory component, such as colorectal cancer (CRC) (1). CRC is the 
third most common cancer and the fourth leading cause of cancer death worldwide and represents 
a clinical model of cancer showing a close relationship with inflammation and environmental 
factors (2). Inflammation is nowadays considered an hallmark of cancer (3), and exacerbated 
inflammatory processes has been reported to favor the insurgence of several types of neoplastic 
2Miccadei et al. Immunomodulatory Effects of ω3 PUFA and Colorectal Cancer
Frontiers in Immunology | www.frontiersin.org November 2016 | Volume 7 | Article 486
diseases, their progression, as well as a worse prognosis for the 
patient with cancer (World Cancer Report, 2014, IARC). Several 
types of inflammation differing by cause, mechanism, outcome, 
and intensity can promote cancer development and progression. 
Interestingly, rising CRC incidence trends are mainly regarded 
as a part of the change in lifestyle, including calorically excessive 
high-fat/low-fiber diet, lack of physical activity, and obesity (4). 
Epidemiological and clinical investigations have consistently 
evidenced a significant relationship between obesity-driven 
inflammation and most steps of CRC development, includ-
ing initiation, promotion, progression, and metastasis (1). 
Furthermore, cancer therapy as well as surgery for cancer resec-
tion can trigger an inflammatory response by causing trauma, 
necrosis, and tissue injury that stimulate tumor re-emergence 
and resistance to therapy (5). In spite of the progress made in 
recent years in cancer treatment, the clinical relevance of the 
conventional therapeutic modalities alone in solid tumors, 
including CRC, still pose major questions due to the high costs 
of drugs and unsatisfactory long-term clinical results (6). Thus, 
due to the impact of inflammation as a risk factor for CRC devel-
opment as well as in the course of the disease, new concepts are 
emerging on the benefits that may derive from the combination 
of conventional CRC treatments with intervention strategies tar-
geted at inhibiting/attenuating chronic inflammation. Notably, 
dietary components influence inflammatory processes including 
intestinal inflammation, and dietary habits have been suggested 
to play a major role in CRC risk (7). Considerable attention has 
therefore been directed toward the ability of nutritional agents 
to target key molecular pathways involved in cancer-related 
inflammation. It has only recently gained acceptance that fatty 
acids (FAs) are major determinants in inflammation and may 
influence the risk of related pathologies. Given their precursor 
status to signaling lipid mediators, FAs act as ligands for key 
immune receptors, and their activation can initiate and perpetu-
ate an innate immune response (8).
DieTARY POLYUnSATURATeD 
FATTY ACiDS
ω3 and ω6 FAs are polyunsaturated fatty acids (PUFA) whose 
definition derives from counting the carbon atoms after the last 
double bond in the end of the fatty acid chain (9). The type of 
response they induce strongly depends on their biochemical 
properties, mainly related to number and position of double 
bonds (10). In this regard, ω3 and ω6 PUFA exhibit different 
behaviors with respect to the inflammatory process, exerting 
anti-inflammatory or pro-inflammatory activity, respectively. 
Owing to the proposed competitive role of ω3 and ω6 PUFA, 
their dietary composition has been suggested to be a biologically 
plausible target for CRC management. ω3 and ω6 FAs represent 
naturally occurring substances required for biological process 
with key roles in phospholipid membrane structure and 
function, cellular signaling, and lipid metabolism (11, 12). 
In  humans, the ω3 α-linolenic acid (ALA, 18:3ω3) as well as 
the ω6 linoleic acid (LA, 18:2ω6), precursors of several PUFA, 
are essential FA that cannot be synthesized by humans and 
must therefore be assumed from dietary sources including fish, 
flaxseeds, walnuts, and algae (9). Several kind of food, rich in 
ω3 PUFA, are typical of the so-called Mediterranean diet (MD). 
Several epidemiological studies have evaluated the effects of this 
dietary pattern as protective against several diseases associated 
with chronic low-grade inflammation such as cancer, diabetes, 
obesity, atherosclerosis, metabolic syndrome, and cognition 
disorders (13). Adherence to traditional MD was found to be 
associated with markedly and significantly reduced incidence 
of cardiovascular diseases and overall cancer (14, 15). Due 
to the poor endogenous conversion of ALA to its longer and 
more highly desaturated FAs, there is considerable debate as to 
whether the longer versions such as eicosapentaenoic acid (EPA, 
20:5ω3) and docosahexaenoic acid (DHA, 22:6ω3) may be con-
sidered semi-essential (16). These PUFA are key components 
of cell membrane, lipoproteins, and adipose tissue (AT) whose 
composition closely reflects the dietary intake (17). For several 
years, ω3 PUFA have been studied extensively for the prevention 
of cardiovascular diseases (18, 19). More recently, their capacity 
to exert anticancer activity has been recognized. A plethora of 
studies pointed to ω3 PUFA and their oxidative metabolites as 
potential anti-inflammatory and anticancer agents, especially 
in areas such as the large bowel, where the influence of orally 
introduced substances is high and tumors show deranged PUFA 
patterns. In particular, modified ω3 and ω6 PUFA profiles have 
been found in serum and cancer tissue of CRC patients, sug-
gesting possible alteration of PUFA metabolism that may play a 
role in inflammation-driven colorectal carcinogenesis (20, 21). 
Overall, these studies suggested that the metabolism of PUFA 
plays a role in inflammation-driven colorectal carcinogenesis 
and is likely influenced by the tumor size. In this regard, it is 
of relevance that ω3/ω6 PUFA ratio of the industrialized diets 
is imbalanced, and this condition results in a well-known pro-
inflammatory effect (22). Noteworthy, a decreased ω3/ω6 PUFA 
ratio of visceral AT correlates with AT inflammatory status in 
CRC patients suggesting that qualitative, more than quantita-
tive, PUFA changes in AT may influence tissue dysfunctions 
potentially linked to inflammatory conditions (23). Likewise, 
the sum of some PUFA [i.e., gamma linolenic acid (GLA), 
Di-homo-gamma linolenic acid (DGLA), and arachidonic acid 
(AA)] in both visceral and subcutaneous AT was found statisti-
cally higher in cancer patients with respect to healthy controls 
(24). Overall, these observations support the concept that 
PUFA derangement occurs not only in tumor tissue but also at 
microenvironment and systemic levels most likely contributing 
to tumor-associated inflammation.
There is now sufficient evidence from prospective studies 
indicating that fish consumption or fish oil ω3 PUFA intake is 
inversely related to CRC incidence in the general population 
(25). However, the results achieved in a recent meta-analysis 
carried out to evaluate the effects of ω3 PUFA on inflammatory 
markers in CRC patients highlighted that the beneficial effects 
of ω3 PUFA rely on supplementation protocols (e.g., dose, dura-
tion, and route of administration), the concomitant anticancer 
regimen adopted, as well as on the confounding effects due to 
other nutrients that might be present in the supplement (26). In 
this regard, it should be taken into account that the observational 
studies carried out to evaluate the potential anticancer effects of 
TAbLe 1 | immunomodulatory effects of ω3 PUFA in monocyte/macrophages and T lymphocytes.
ω3 PUFA exposure experimental/animal model Observed effect Suggested mechanism Reference
DHAa, EPAa MU and HU monocytic cell lines; 
MU and HU primary monocyte/
Mφ, C57BL/6 mice
↓ inflammasome activation GPR120-β arrestin-2-mediated 
NF-kB inhibition
(34–36)
Enhanced autophagy
Impaired TLR2/TLR1 
dimerization
Isocaloric HFD-containing 27% 
menhaden fish oil (16% EPA, 9% 
DHA); isocaloric ω3 PUFA-enriched 
diet (3% menhaden fish-oil + 7% 
safflower oil)
C57BL/6 mice ↓ leukocyte chemotaxis GPR120, β arrestin-2 (37, 38)
NF-kB and STAT3 inhibition
DHAa, EPAa MU monocytic cell lines and 
primary Mφ
↑ efferocytic activity of Mφ PPARγ and AKT activation (39, 40)
DHAa, EPAa, isocaloric HFD-
containing 27% menhaden fish oil 
(16% EPA, 9% DHA); HFD + DHAa
MU monocytic cell lines and 
primary Mφ
↑ M2 Mφ polarization GPR120, β arrestin-2 (37, 40–42)
C57BL/6 mice
DHAa, EPAa, ω3 PUFA-enriched 
dietb, DHA-enriched diet 
(omegavie DHA90 TG)
BALB/c and C57BL/6 mice MU 
spleen and bone marrow DC
↓ T cell activation
↑ Th2 lymphocyte polarization
↓ Th17 lymphocyte polarization
↑ expression and generation of Treg
↓ Treg suppressive and migratory 
function
Interference with STAT3 
signaling pathway via 
enhancement of PPARγ-induced 
SOCS3
(43–51)
M2 Mφ mediated
↓ DC activation
↓ DC-mediated T cell activation
↑ DC-mediated Treg expansion
The table shows a summary of the main publications on the immunomodulatory effects of ω3 PUFA in monocyte/macrophages and T lymphocytes, including both in vitro studies 
and in vivo animal models.
MU, murine; HU, human; Mφ, macrophage; DC, dendritic cell; HFD, high fat diet; GPR120, G protein-coupled receptor 120.
aChemically synthesized.
bω3 PUFA source: perilla seed oil, menhaden fish oil, and EPAX oil (EPAX-7010) containing ~85% ω3 PUFA (70% EPA, 12% DHA).
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ω3 PUFA might have been limited by the insufficient homogene-
ity of the observations. An explanation for such heterogeneity 
relies likely on the inherent difficulties associated with epidemi-
ology, including the confounding and dietary pattern context, 
measurement error, level of intake, and genetic polymorphisms 
(26, 27).
Despite the majority of studies has proven that ω3 PUFA 
administration is not toxic or carcinogenic, it is hard to imagine 
that these compounds could be exploited alone in the treatment 
of cancer. However, growing epidemiological, experimental, 
and clinical evidence showing the beneficial effects of ω3 PUFA 
in several stages of CRC management represent a solid rationale 
for their exploitation in therapeutic combinatory strategies 
(28). The antineoplastic effects of ω3 PUFA have been studied 
for many years, and multiple biological mechanisms have been 
suggested to explain their inhibitory effects on cancer cell 
growth (29, 30). However, in recent years, growing attention 
has been given to the antineoplastic activity of ω3 PUFA related 
to the action of these bioactive molecules on inflammatory 
process, due to the pathogenic role of inflammation in the 
development of many kinds of tumors. ω3 PUFA, particularly 
EPA and DHA, have emerged as nutrients capable of modulat-
ing both metabolic and immune processes. As summarized in 
Table 1, these PUFA are able to modulate a number of aspects 
of the inflammatory process ranging from inflammasome 
activation, leukocyte recruitment, and production of immune 
mediators, to differentiation and activation of immune cells. ω3 
PUFA effects are mediated by different mechanisms including 
both extracellular (e.g., GPR120) (31) and intracellular (e.g., 
PPARγ) receptors that control inflammatory cell signaling and 
gene expression (32). In spite of many efforts, it remains to be 
fully defined how these compounds succeed in influencing 
such a variety of molecular pathways and cell/tissue functions 
with pleiotropic beneficial effects, and how these mechanisms 
are interconnected. Some of the ω3 PUFA-mediated events 
appear to rely, at least in part, on changes in FA composition of 
membrane phospholipids, relevant for the production of lipid 
mediators, and formation of lipid rafts in response to inflam-
matory stimuli (33).
PROTeCTive AnTi-inFLAMMATORY 
eFFeCTS OF ω3 PUFA in 
COLOReCTAL CAnCeR
Considerable debate still exists on the mechanisms underlying the 
protective effects exerted by the ω3 PUFA on the establishment/
progression of inflammation and cancer (29). Furthermore, the 
precise mechanism that operates at specific body district, such 
as the intestine, remains to be defined. Several mechanisms have 
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been proposed to explain the capacity of ω3 PUFA to interfere 
with important steps of CRC carcinogenesis including altera-
tions of the cellular redox state and modulation of membrane 
dynamics, and surface receptor function which regulate cell 
proliferation and apoptosis. Due to the close association of CRC 
with inflammation, the capacity of ω3 PUFA to modulate some 
aspects of inflammation and immune response is becoming 
increasingly important. In this regard, it is of interest that ω3 
PUFA inhibit agonist-induced activation of pattern recognition 
receptors, thus dampening inflammation (52). However, only few 
studies focused on the role of PUFA-mediated immunomodula-
tory effects in the therapy of CRC.
Due to the abundance of double bonds, EPA and DHA 
are susceptible to oxidation and can undergo spontaneous 
non-enzymatic peroxidation or enzymatic oxidation giving 
rise to a variety of bioactive lipids that induce inflammation, 
tumorigenesis, and thrombosis, as well as to mediators with 
antitumorigenic, pro-resolution properties (53, 54). One of 
the main mechanisms by which ω3 PUFA exert their anti-
inflammatory activity involves enzymatic pathways that are 
hyper-activated in CRC (55), such as cyclooxygenase (COX) 
and lipoxygenase (LOX), and leads to prostaglandin E2 (PGE2) 
production, a potent pro-inflammatory and procarcinogenic 
agent. EPA and DHA have been shown to inhibit COX-2 expres-
sion in CRC cells (56), and this effect has been attributed to ω3 
PUFA capacity to displace ω6 PUFA, in particular AA, from 
membranes. This metabolic competition is due to structural 
similarity of EPA and AA, which compete with each other for 
the same enzymes, COX, and LOX, a very important event in 
tumor development (57). Furthermore, supplementation with 
ω3 PUFA significantly decreases AA-derived eicosanoids, 
while increasing EPA-derived eicosanoids, shifting the balance 
toward a reduced level of inflammation (58). Interestingly, 
aspirin, a non-steroidal anti-inflammatory drug, possesses both 
COX and LOX inhibitory action, and enhances the production 
of the anti-inflammatory lipid mediator lipoxin A4. Likewise, 
anti-inflammatory compounds are formed from EPA and 
DHA by the action of aspirin termed as resolvins (from EPA 
and DHA) and protectins and maresins from DHA (59, 60). 
Of note, regular aspirin use substantially reduces the risk of 
CRC (61). Pro-inflammatory cytokines and tumor-infiltrating 
myeloid and immune cells play critical roles in almost every 
developmental stages of inflammation-related cancers, from 
initiation, promotion, and progression to malignant metastasis 
(1). A recently published meta-analysis of the ω3 PUFA effects 
on inflammatory markers highlighted a decreased level of some 
inflammatory mediators (cytokines or acute phase proteins) 
in CRC patients who received ω3 PUFA supplementation 
(26). Likewise, a recent in  vitro study described a new anti-
inflammatory and anticancer properties of DHA. Fluckiger and 
colleagues reported that inhibition of colon cancer growth and 
activation of apoptosis by DHA involve autocrine production of 
TNFα via microRNA (miR)-21 (62).
Another mechanism involved in anti-inflammatory and 
potentially antineoplastic effects of ω3 PUFA regards the pos-
sibility that these compounds may modulate epigenetically 
(through DNA methylation, acetylation modifications, and 
miR gene regulation) the expression of crucial genes involved 
in cellular processes associated with colorectal carcinogen-
esis (63–65). More recently, the epigenetic regulation of gene 
expression and the polarization of macrophages toward pro-
resolving M2 phenotype have emerged as novel mechanisms 
explaining the antineoplastic effects of ω3 PUFA at the colon 
level, although additional studies are needed for a deeper 
comprehension of this issue (30). Finally, the capacity of ω3 
PUFA to modulate inflammatory pathways and to generate 
lipid mediators critical for the resolution of inflammation (e.g., 
resolvins, protectins, and maresins) has gained attention as a 
main mechanism involved in the beneficial effects of ω3 PUFA 
against CRC (66).
ω3 PUFA AS POTenTiAL ADJUvAnTS in 
THe THeRAPY OF CRC
Fatty acids may influence carcinogenesis through various mecha-
nisms. EPA and DHA are incorporated into cellular membranes 
and through the production of lipid mediators and may exert 
anticancer properties by affecting gene expression or activating 
signal transduction molecules involved in the control of cell 
proliferation, differentiation, apoptosis, and metastasis. These 
properties of ω3 PUFA suggest that they will have important 
therapeutic potential in cancer management.
Patients undergoing surgery are at risk of developing com-
plications in the postoperative period partly caused by changes 
in the immune response following surgery (67). Thus, initially, 
a hyper-inflammatory response followed by a phase of relative 
immune incompetence occurs in relation to major surgery (68). 
Patients who undergo surgery for CRC have a 30% risk of infec-
tious complications, and anastomotic leakages are seen in as 
many as 15% of patients (69).
Initial studies indicated that administration of PUFA-
enriched diets leads to increased incorporation of EPA 
and DHA not only in liver and gut mucosa tissue but also 
in tumor tissue in patients with solid tumors of the upper 
gastrointestinal tract (70). This observation suggested that 
preoperative administration of oral PUFA-enriched diets could 
have an impact on the postoperative inflammatory response 
after major abdominal surgery. Subsequently, in a prospective 
randomized, double-blind, single-center, placebo-controlled 
study, it was demonstrated a higher total marine ω3 PUFA 
content in the colonic mucosa, but not in the muscular layer, 
after 7  days of oral EPA +  DHA supplementation to patients 
admitted for elective CRC surgery (71). Furthermore, providing 
ω3 PUFA daily for 7 days before surgery resulted in a significant 
decrease in the formation of the pro-inflammatory leukotriene 
B4 (LTB4) from neutrophils with a simultaneous increased 
production of LTB5. However, the clinical consequences of 
these changes are still unknown as no correlations between 
values of LTB4 or LTB4/LTB5, and postoperative complication 
rates were found (72). Likewise, the higher incorporation of 
EPA, DHA, and docosapentaenoic acid in granulocytes of the 
ω3 PUFA-enriched supplement group of CRC patients was not 
associated with improved postoperative outcomes (69). Thus, 
the effects of ω3 PUFA on preoperative complications need to 
5Miccadei et al. Immunomodulatory Effects of ω3 PUFA and Colorectal Cancer
Frontiers in Immunology | www.frontiersin.org November 2016 | Volume 7 | Article 486
be investigated in larger trials and for a longer period (months) 
of ω3 PUFA intake to clearly establish whether LTB formation 
from activated neutrophils is/is not an important determinant 
of surgical complications.
Several studies highlighted the beneficial effect of ω3 PUFA 
as chemopreventive and chemotherapeutic agents in the treat-
ment of several chronic pathologies including cancer providing 
evidence for a potential use of these compounds to enhance 
chemo/radiotherapy efficacy and reduce the risk of tumor 
recurrence (73). Furthermore, several studies demonstrated 
that EPA and DHA, having immunomodulatory capacity, act 
to reduce inflammation, even when associated with chemo/
radiotherapy immune suppression in lung (74, 75), and in 
other cancers (73).
In particular, Xue and colleagues evaluated whether ω3 
PUFA supplementation could affect the efficacy of a cyclical 
combination treatment with Irinotecan (CPT-11)/5-fluorouracil 
(5-FU) in a rat CRC model. Administration of a diet enriched 
with ω3 PUFA prior to initiating chemotherapy, inhibited tumor 
growth, while, during chemotherapy, ω3 PUFA-enriched diet 
enhanced tumor chemosensitivity and reduced body weight loss 
with respect to control diet fed rats (76). Other studies addressed 
the issue of whether supplementation with ω3 PUFA to CRC 
patients undergoing chemotherapy could induce changes in 
inflammation markers, such as the ratio of C reactive protein 
(CRP) to albumin, considered a relevant clinical/inflammatory 
marker. In this respect, some clinical trials demonstrated that 
EPA and DHA supplementation during chemotherapeutic 
treatments improved CRP values, CRP/albumin status, and 
positively modulated the nutritional status of CRC patients 
(77, 78). Likewise, evaluation of clinical outcomes during and 
after chemotherapy in CRC patients supplemented with fish oil 
containing EPA and DHA during the first 9 weeks of treatment 
unraveled that the time to tumor progression was significantly 
longer in the supplemented with respect to the control group 
(79). Interestingly, a recent phase II double-blind randomized, 
placebo-controlled trial of EPA administration to advanced 
CRC patients undergoing liver resection surgery demonstrated 
that EPA is incorporated into secondary CRC tissue and has 
systemic anti-inflammatory activity. In particular, a clear-cut 
decrease of the urinary metabolite PGE-M, reflecting systemic 
PGE2 levels, as well as a reversible reduction in NF-kB binding 
in peripheral blood leukocytes was observed in EPA-treated 
patients with respect to the placebo group (80). Overall, these 
observations that supplementation may represent an innova-
tive combination therapy strategy contributing to delay tumor 
progression and likely enhancing the antineoplastic activity of 
chemotherapeutic drugs. The design and main hallmarks of 
clinical trials performed on CRC patients supplemented with 
ω3 PUFA, described above, are summarized in Table 2.
In the last years, many studies have highlighted the presence 
of cancer stem cells (CSC) in most tumors, including CRC. 
TAbLe 2 | Clinical effects of ω3 PUFA in CRC patients.
ω3 PUFA daily 
treatment
Surgery n 
Subjects
Timing/
duration
Chemotherapy Observed effect Outcome measures Reference
1 g DHA + 2 g 
EPA orally
Yes 148 7 days 
pre-surgery
No Potential beneficial effect on local 
immune function
ω3 PUFA content in the 
colonic mucosa and 
muscular layer
(71)
1 g DHA + 2 g 
EPA orally
Yes 148 7 days 
pre-surgery
No Anti-inflammatory effects Inflammatory markers (72)
5-HEPE ↑
LTB4/%-HETE ↓
1 g DHA + 2 g 
EPA orally
Yes 148 7 days  
pre- and 
7 days 
post-surgery
No No significant difference 
between group in infectious or 
non-infectious post-operative 
complications
Levels of ω3 PUFA into 
granulocytes
(69)
0.6 g EPA/DHA 
(fish oil) orally
No 23 63 days 5-FU + irinotecan 
+ folinic acid
Positive modulation of nutritional 
status. CRP/albumin ↓
Evaluation of nutritional status 
and inflammatory markers
(77)
0.6 g EPA/DHA 
(fish oil) orally
No 11 63 days CAPE + OXA 
+ 5-FU + leucovorin
Improved CRP values,  
CRP/albumin status, plasma 
fatty acid profile, and potentially 
prevented weight loss during 
treatment
Evaluation of inflammatory 
markers and nutritional status
(78)
0.6 g EPA/DHA 
(fish oil) orally
No 30 63 days Standard 
chemotherapy
Delayed tumor progression time 
by enhancing the antineoplastic 
action of chemotherapy
Evaluation of tumor 
progression time and CEA 
values after chemotherapy
(79)
2 g EPA-FFAa 
orally
Yes 88 Median 
30 days 
pre-operative
No Preoperative treatment may 
have prolonged benefit on post-
operative overall and disease-free 
survival
Ki67, CD31, and PGE2 
levels. Survival statistical 
analysis (overall and  
disease-free survival)
(80)
aALFA (SLA Pharma AG, Liestel, Switzerland).
5-HEPE, 5-hydroxyeicosatetraenoic acid; LTB4, leukotriene B4; 5-HETE, 5-hydroxyeicosatetraenoic acid; 5-FU, 5-fluorouracil; CAPE, capecitabine (Xeloda); OXA, oxaloplatin; CRP, 
C reactive protein; CEA, carcinoembryonic antigen; PGE2, prostaglandin E.2.
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